AMSTERDAM — Six weeks of triple combination therapy induced sustained virologic response in a cohort of patients with genotype 1 HCV but not genotype 3, according to data presented at the International Liver Congress.
“We observed 100% SVR24 for genotype 1, treatment-naive, non-cirrhotic patients who received a triple combination for either 8 or 6 weeks,” Ed Gane, MD, professor of medicine and chief hepatologist, transplant physician and deputy director of the New Zealand Liver Transplant Unit at the University of Auckland in New Zealand, said in his presentation. “However, when you remove simeprevir, the efficacy in genotype 1 is reduced. There was also reduced efficacy of a three-DAA regimen in genotype 3 for 8 weeks.”
Gane said that the rationale for the current study was to determine whether combining three different drugs with different mechanisms of action could allow the duration of therapy to be shortened. In the current study, AL-335 (Achillion) and odalasvir (Achillion) with or without Olysio (simeprevir, Janssen) were studied in a cohort of patients with genotype 1 and 3 disease in New Zealand.
Continue reading....
Meeting Coverage HealioInternational Liver Congress
No comments:
Post a Comment